{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:55:30Z","timestamp":1789692930753,"version":"4.0.1"},"reference-count":114,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.1248\/bpb.b23-00642","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:17:12Z","timestamp":1740781032000},"page":"213-221","source":"Crossref","is-referenced-by-count":7,"title":["Colistin Resistance in &lt;i&gt;Acinetobacter baumannii&lt;\/i&gt;: Basic and Clinical Insights"],"prefix":"10.1248","volume":"48","author":[{"given":"Go","family":"Kamoshida","sequence":"first","affiliation":[{"name":"Department of Infection Control Science, Meiji Pharmaceutical University, 2\u2013522\u20131 Noshio, Kiyose, Tokyo 204\u20138588, Japan"},{"name":"Laboratory of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical University, 5 Misasagi-nakauchi-cho, Yamashina-ku, Kyoto 607\u20138412, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriteru","family":"Yamada","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical University, 5 Misasagi-nakauchi-cho, Yamashina-ku, Kyoto 607\u20138412, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical University, 5 Misasagi-nakauchi-cho, Yamashina-ku, Kyoto 607\u20138412, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinnosuke","family":"Yahiro","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Infection Control Sciences, Kyoto Pharmaceutical University, 5 Misasagi-nakauchi-cho, Yamashina-ku, Kyoto 607\u20138412, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Meiji Pharmaceutical University, 2\u2013522\u20131 Noshio, Kiyose, Tokyo 204\u20138588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Peleg AY, Seifert H, Paterson DL. <i>Acinetobacter baumannii<\/i>: emergence of a successful pathogen. <i>Clin. Microbiol. Rev.<\/i>, <b>21<\/b>, 538\u2013582 (2008).","DOI":"10.1128\/CMR.00058-07"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chapartegui-Gonz\u00e1lez I, Lazaro-Diez M, Bravo Z, Navas J, Icardo JM, Ramos-Vivas J. <i>Acinetobacter baumannii<\/i> maintains its virulence after long-time starvation. <i>PLOS ONE<\/i>, <b>13<\/b>, e0201961 (2018).","DOI":"10.1371\/journal.pone.0201961"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Antunes LC, Visca P, Towner KJ. <i>Acinetobacter baumannii<\/i>: evolution of a global pathogen. <i>Pathog. Dis.<\/i>, <b>71<\/b>, 292\u2013301 (2014).","DOI":"10.1111\/2049-632X.12125"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Munoz-Price LS, Weinstein RA. Acinetobacter infection. <i>N. Engl. J. Med.<\/i>, <b>358<\/b>, 1271\u20131281 (2008).","DOI":"10.1056\/NEJMra070741"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant <i>Acinetobacter baumannii<\/i>. <i>Nat. Rev. Microbiol.<\/i>, <b>5<\/b>, 939\u2013951 (2007).","DOI":"10.1038\/nrmicro1789"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Castanheira M, Mendes RE, Gales AC. Global Epidemiology and Mechanisms of Resistance of <i>Acinetobacter baumannii<\/i>-calcoaceticus Complex. <i>Clin. Infect. Dis.<\/i>, <b>76<\/b> (Suppl. 2), S166\u2013S178 (2023).","DOI":"10.1093\/cid\/ciad109"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Le\u00e3o AC, Menezes PR, Oliveira MS, Levin AS. <i>Acinetobacter<\/i> spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. <i>BMC Infect. Dis.<\/i>, <b>16<\/b>, 386 (2016).","DOI":"10.1186\/s12879-016-1695-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, Wenzel RP, Seifert H. Nosocomial bloodstream infections due to <i>Acinetobacter baumannii<\/i>, <i>Acinetobacter pittii<\/i> and <i>Acinetobacter nosocomialis<\/i> in the United States. <i>J. Infect.<\/i>, <b>64<\/b>, 282\u2013290 (2012).","DOI":"10.1016\/j.jinf.2011.12.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to <i>Acinetobacter baumannii<\/i>: epidemiology, clinical features and treatment. <i>Clin. Microbiol. Infect.<\/i>, <b>8<\/b>, 687\u2013693 (2002).","DOI":"10.1046\/j.1469-0691.2002.00487.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant <i>Acinetobacter baumannii<\/i>: a challenge in the intensive care unit. <i>Front. Microbiol.<\/i>, <b>13<\/b>, 1045206 (2022).","DOI":"10.3389\/fmicb.2022.1045206"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nguyen M, Joshi SG. Carbapenem resistance in <i>Acinetobacter baumannii<\/i>, and their importance in hospital-acquired infections: a scientific review. <i>J. Appl. Microbiol.<\/i>, <b>131<\/b>, 2715\u20132738 (2021).","DOI":"10.1111\/jam.15130"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant <i>Acinetobacter baumannii<\/i>. <i>Microb. Genom.<\/i>, <b>5<\/b>, e000306 (2019).","DOI":"10.1099\/mgen.0.000306"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant <i>Acinetobacter baumannii<\/i>. <i>J. Antimicrob. Chemother.<\/i>, <b>65<\/b>, 233\u2013238 (2010).","DOI":"10.1093\/jac\/dkp428"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Asokan GV, Ramadhan T, Ahmed E, Sanad H. WHO global priority pathogens list: a bibliometric analysis of medline-pubmed for knowledge mobilization to infection prevention and control practices in Bahrain. <i>Oman Med. J.<\/i>, <b>34<\/b>, 184\u2013193 (2019).","DOI":"10.5001\/omj.2019.37"},{"key":"15","unstructured":"15) Tacconelli E, Carrara E, Savoldi A, <i>et al.<\/i> Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infect. Dis.<\/i>, <b>18<\/b>, 318\u2013327 (2018)."},{"key":"16","unstructured":"16) CDC. \u201cAntibiotic resistance threats in the Unisted States (2019).\u201d: &lt;https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html&gt;, accessed 20 September, 2023."},{"key":"17","unstructured":"17) AMED. \u201cList of Pathogen (2021).\u201d: &lt;https:\/\/id3catalyst.jp\/apid\/en\/list.html&gt;, accessed 20 September, 2023."},{"key":"18","unstructured":"18) Koyama Y. A new antibiotic \u2018colistin\u2019 produced by spore-forming soil bacteria. <i>J. Antibiotics<\/i>, <b>3<\/b>, 457\u2013458 (1950)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. <i>Antimicrob. Agents Chemother.<\/i>, <b>53<\/b>, 3430\u20133436 (2009).","DOI":"10.1128\/AAC.01361-08"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. <i>Int. J. Antimicrob. Agents<\/i>, <b>25<\/b>, 11\u201325 (2005).","DOI":"10.1016\/j.ijantimicag.2004.10.001"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. <i>Expert Rev. Anti Infect. Ther.<\/i>, <b>10<\/b>, 917\u2013934 (2012).","DOI":"10.1586\/eri.12.78"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nation RL, Li J. Colistin in the 21st century. <i>Curr. Opin. Infect. Dis.<\/i>, <b>22<\/b>, 535\u2013543 (2009).","DOI":"10.1097\/QCO.0b013e328332e672"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. <i>Clin. Microbiol. Rev.<\/i>, <b>21<\/b>, 449\u2013465 (2008).","DOI":"10.1128\/CMR.00006-08"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. <i>Lancet Infect. Dis.<\/i>, <b>6<\/b>, 589\u2013601 (2006).","DOI":"10.1016\/S1473-3099(06)70580-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) El-Sayed Ahmed MAE, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000\u20132019). <i>Emerg. Microbes Infect.<\/i>, <b>9<\/b>, 868\u2013885 (2020).","DOI":"10.1080\/22221751.2020.1754133"},{"key":"26","unstructured":"26) WHO. \u201cCritically Important Antimicrobials for Human Medicine: 3rd Revision.\u201d &lt;https:\/\/www.who.int\/publications\/i\/item\/9789241504485&gt;. (2012)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum beta-lactamase producing enterobacterilas (ESBL-E), carbapenem-resistant enterobacterials (CRE), and <i>Pseudomonas aeruginosa<\/i> with dificult-to-treat resistance (DTR-P. aeruginosa). <i>Clin. Infect. Dis.<\/i>, <b>72<\/b>, e169\u2013e183 (2021).","DOI":"10.1093\/cid\/ciaa1478"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. <i>Clin. Infect. Dis.<\/i>, <b>69<\/b> (Suppl. 7), S565\u2013S575 (2019).","DOI":"10.1093\/cid\/ciz830"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Doi Y, Murray GL, Peleg AY. <i>Acinetobacter baumannii<\/i>: evolution of antimicrobial resistance-treatment options. <i>Semin. Respir. Crit. Care Med.<\/i>, <b>36<\/b>, 85\u201398 (2015).","DOI":"10.1055\/s-0034-1398388"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. <i>Clin. Infect. Dis.<\/i>, <b>40<\/b>, 1333\u20131341 (2005).","DOI":"10.1086\/429323"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy <i>versus<\/i> colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant <i>Acinetobacter baumannii<\/i>: A randomised controlled trial. <i>J. Glob. Antimicrob. Resist.<\/i>, <b>17<\/b>, 66\u201371 (2019).","DOI":"10.1016\/j.jgar.2018.11.016"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of <i>Acinetobacter baumannii<\/i>: clinical reports, mechanisms and antimicrobial strategies. <i>J. Antimicrob. Chemother.<\/i>, <b>67<\/b>, 1607\u20131615 (2012).","DOI":"10.1093\/jac\/dks084"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. <i>Ann. Pharmacother.<\/i>, <b>33<\/b>, 960\u2013967 (1999).","DOI":"10.1345\/aph.18426"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hamel M, Rolain JM, Baron SA. The history of colistin resistance mechanisms in bacteria: progress and challenges. <i>Microorganisms<\/i>, <b>9<\/b>, 442 (2021).","DOI":"10.3390\/microorganisms9020442"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Purcell AB, Simpson BW, Trent MS. Impact of the cAMP-cAMP receptor protein regulatory complex on lipopolysaccharide modifications and polymyxin B resistance in <i>Escherichia coli<\/i>. <i>J. Bacteriol.<\/i>, <b>205<\/b>, e0006723 (2023).","DOI":"10.1128\/jb.00067-23"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chen HD, Groisman EA. The biology of the PmrA\/PmrB two-component system: the major regulator of lipopolysaccharide modifications. <i>Annu. Rev. Microbiol.<\/i>, <b>67<\/b>, 83\u2013112 (2013).","DOI":"10.1146\/annurev-micro-092412-155751"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Huang J, Li C, Song J, Velkov T, Wang L, Zhu Y, Li J. Regulating polymyxin resistance in Gram-negative bacteria: roles of two-component systems PhoPQ and PmrAB. <i>Future Microbiol.<\/i>, <b>15<\/b>, 445\u2013459 (2020).","DOI":"10.2217\/fmb-2019-0322"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gunn JS. The <i>Salmonella<\/i> PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. <i>Trends Microbiol.<\/i>, <b>16<\/b>, 284\u2013290 (2008).","DOI":"10.1016\/j.tim.2008.03.007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. Resistance to colistin in <i>Acinetobacter baumannii<\/i> associated with mutations in the PmrAB two-component system. <i>Antimicrob. Agents Chemother.<\/i>, <b>53<\/b>, 3628\u20133634 (2009).","DOI":"10.1128\/AAC.00284-09"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Farajnia S, Lotfi F, Dehnad A, Shojaie M, Raisi R, Rahbarnia L, Bazmani A, Naghili B, Shiry S. The molecular characterization of colistin-resistant isolates of <i>Acinetobacter baumannii<\/i> from patients at intensive care units. <i>Iran. J. Microbiol.<\/i>, <b>14<\/b>, 319\u2013327 (2022).","DOI":"10.18502\/ijm.v14i3.9768"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Srisakul S, Wannigama DL, Higgins PG, Hurst C, Abe S, Hongsing P, Saethang T, Luk-In S, Liao T, Kueakulpattana N, Shein AMS, Gan L, Kupwiwat R, Tanasatitchai C, Wapeesittipan P, Phattharapornjaroen P, Badavath VN, Leelahavanichkul A, Chatsuwan T. Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in <i>Acinetobacter baumannii<\/i> clinical isolates with colistin-sulbactam combination therapy. <i>Sci. Rep.<\/i>, <b>12<\/b>, 11390 (2022).","DOI":"10.1038\/s41598-022-15386-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Khoshbayan A, Shariati A, Shahmoradi S, Baseri Z, Mozafari H, Darban-Sarokhalil D. Prevalence and molecular mechanisms of colistin resistance in <i>Acinetobacter baumannii<\/i> clinical isolates in Tehran, Iran. <i>Acta Microbiol. Immunol. Hung.<\/i>, <b>68<\/b>, 262\u2013266 (2021).","DOI":"10.1556\/030.2021.01420"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Gerson S, Lucassen K, Wille J, Nodari CS, Stefanik D, Nowak J, Wille T, Betts JW, Roca I, Vila J, Cisneros JM, Seifert H, Higgins PG. Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of <i>Acinetobacter baumannii<\/i>. <i>Int. J. Antimicrob. Agents<\/i>, <b>55<\/b>, 105862 (2020).","DOI":"10.1016\/j.ijantimicag.2019.105862"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. <i>Front. Microbiol.<\/i>, <b>5<\/b>, 643 (2014).","DOI":"10.3389\/fmicb.2014.00643"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. Phosphoethanolamine modification of lipid A in colistin-resistant variants of <i>Acinetobacter baumannii<\/i> mediated by the pmrAB two-component regulatory system. <i>Antimicrob. Agents Chemother.<\/i>, <b>55<\/b>, 3370\u20133379 (2011).","DOI":"10.1128\/AAC.00079-11"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant <i>Acinetobacter baumannii<\/i>. <i>Diagn. Microbiol. Infect. Dis.<\/i>, <b>82<\/b>, 222\u2013226 (2015).","DOI":"10.1016\/j.diagmicrobio.2015.03.013"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, Doi Y, Ernst RK. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of <i>Acinetobacter baumannii<\/i>. <i>Antimicrob. Agents Chemother.<\/i>, <b>57<\/b>, 4831\u20134840 (2013).","DOI":"10.1128\/AAC.00865-13"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Leung LM, McElheny CL, Gardner FM, Chandler CE, Bowler SL, Mettus RT, Spychala CN, Fowler EL, Opene BNA, Myers RA, Goodlett DR, Doi Y, Ernst RK. A prospective study of <i>Acinetobacter baumannii<\/i> complex isolates and colistin susceptibility monitoring by mass spectrometry of microbial membrane glycolipids. <i>J. Clin. Microbiol.<\/i>, <b>57<\/b>, e01100\u201318 (2019).","DOI":"10.1128\/JCM.01100-18"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Chin CY, Gregg KA, Napier BA, Ernst RK, Weiss DS. A PmrB-regulated deacetylase required for lipid A modification and polymyxin resistance in <i>Acinetobacter baumannii<\/i>. <i>Antimicrob. Agents Chemother.<\/i>, <b>59<\/b>, 7911\u20137914 (2015).","DOI":"10.1128\/AAC.00515-15"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Yamada N, Kamoshida G, Shiraishi T, Yamaguchi D, Matsuoka M, Yamauchi R, Kanda N, Kamioka R, Takemoto N, Morita Y, Fujimuro M, Yokota S-i, Yahiro K. PmrAB, the two-component system of <i>Acinetobacter baumannii<\/i>, controls the phosphoethanolamine modification of lipooligosaccharide in response to metal ions. <i>J. Bacteriol.<\/i>, <b>206<\/b>, e0043523 (2024).","DOI":"10.1128\/jb.00435-23"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Potron A, Vuillemenot JB, Puja H, Triponney P, Bour M, Valot B, Amara M, Cavalie L, Bernard C, Parmeland L, Reibel F, Larrouy-Maumus G, Dortet L, Bonnin RA, Plesiat P. ISAba1-dependent overexpression of eptA in clinical strains of <i>Acinetobacter baumannii<\/i> resistant to colistin. <i>J. Antimicrob. Chemother.<\/i>, <b>74<\/b>, 2544\u20132550 (2019).","DOI":"10.1093\/jac\/dkz241"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Trebosc V, Gartenmann S, Totzl M, Lucchini V, Schellhorn B, Pieren M, Lociuro S, Gitzinger M, Tigges M, Bumann D, Kemmer C. Dissecting colistin resistance mechanisms in extensively drug-resistant <i>Acinetobacter baumannii<\/i> clinical isolates. <i>MBio<\/i>, <b>10<\/b>, e01083\u201319 (2019).","DOI":"10.1128\/mBio.01083-19"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. <i>Lancet Infect. Dis.<\/i>, <b>16<\/b>, 161\u2013168 (2016).","DOI":"10.1016\/S1473-3099(15)00424-7"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Martins-Sorenson N, Snesrud E, Xavier DE, Cacci LC, Iavarone AT, McGann P, Riley LW, Moreira BM. A novel plasmid-encoded mcr-4.3 gene in a colistin-resistant <i>Acinetobacter baumannii<\/i> clinical strain. <i>J. Antimicrob. Chemother.<\/i>, <b>75<\/b>, 60\u201364 (2020).","DOI":"10.1093\/jac\/dkz413"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Hameed F, Khan MA, Muhammad H, Sarwar T, Bilal H, Rehman TU. Plasmid-mediated mcr-1 gene in <i>Acinetobacter baumannii<\/i> and Pseudomonas aeruginosa: first report from Pakistan. <i>Rev. Soc. Bras. Med. Trop.<\/i>, <b>52<\/b>, e20190237 (2019).","DOI":"10.1590\/0037-8682-0237-2019"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Steeghs L, den Hartog R, den Boer A, Zomer B, Roholl P, van der Ley P. Meningitis bacterium is viable without endotoxin. <i>Nature<\/i>, <b>392<\/b>, 449\u2013450 (1998).","DOI":"10.1038\/33046"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Peng D, Hong W, Choudhury BP, Carlson RW, Gu XX. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. <i>Infect. Immun.<\/i>, <b>73<\/b>, 7569\u20137577 (2005).","DOI":"10.1128\/IAI.73.11.7569-7577.2005"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Vila-Farr\u00e9s X, Ferrer-Navarro M, Callarisa AE, Marti S, Espinal P, Gupta S, Rolain JM, Giralt E, Vila J. Loss of LPS is involved in the virulence and resistance to colistin of colistin-resistant <i>Acinetobacter nosocomialis<\/i> mutants selected in vitro. <i>J. Antimicrob. Chemother.<\/i>, <b>70<\/b>, 2981\u20132986 (2015).","DOI":"10.1093\/jac\/dkv244"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. Colistin resistance in <i>Acinetobacter baumannii<\/i> is mediated by complete loss of lipopolysaccharide production. <i>Antimicrob. Agents Chemother.<\/i>, <b>54<\/b>, 4971\u20134977 (2010).","DOI":"10.1128\/AAC.00834-10"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Kamoshida G, Yamada N, Nakamura T, Yamaguchi D, Kai D, Yamashita M, Hayashi C, Kanda N, Sakaguchi M, Morimoto H, Sawada T, Okada T, Kaya Y, Takemoto N, Yahiro K. Preferential selection of low-frequency, lipopolysaccharide-modified, colistin-resistant mutants with a combination of antimicrobials in <i>Acinetobacter baumannii<\/i>. <i>Microbiol. Spectr.<\/i>, <b>10<\/b>, e0192822 (2022).","DOI":"10.1128\/spectrum.01928-22"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Kamoshida G, Akaji T, Takemoto N, Suzuki Y, Sato Y, Kai D, Hibino T, Yamaguchi D, Kikuchi-Ueda T, Nishida S, Unno Y, Tansho-Nagakawa S, Ubagai T, Miyoshi-Akiyama T, Oda M, Ono Y. Lipopolysaccharide-deficient <i>Acinetobacter baumannii<\/i> due to colistin resistance is killed by neutrophil-produced lysozyme. <i>Front. Microbiol.<\/i>, <b>11<\/b>, 573 (2020).","DOI":"10.3389\/fmicb.2020.00573"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Carretero-Ledesma M, Garcia-Quintanilla M, Martin-Pena R, Pulido MR, Pachon J, McConnell MJ. Phenotypic changes associated with Colistin resistance due to lipopolysaccharide loss in <i>Acinetobacter baumannii<\/i>. <i>Virulence<\/i>, <b>9<\/b>, 930\u2013942 (2018).","DOI":"10.1080\/21505594.2018.1460187"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Powers MJ, Trent MS. Expanding the paradigm for the outer membrane: <i>Acinetobacter baumannii<\/i> in the absence of endotoxin. <i>Mol. Microbiol.<\/i>, <b>107<\/b>, 47\u201356 (2018).","DOI":"10.1111\/mmi.13872"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Boll JM, Crofts AA, Peters K, Cattoir V, Vollmer W, Davies BW, Trent MS. A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient <i>Acinetobacter baumannii<\/i>. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>113<\/b>, E6228\u2013E6237 (2016).","DOI":"10.1073\/pnas.1611594113"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Simpson BW, Nieckarz M, Pinedo V, McLean AB, Cava F, Trent MS. <i>Acinetobacter baumannii<\/i> can survive with an outer membranel lacking lipooligosaccharide due to structural support from elongasome peptidoglycan synthesis. <i>MBio<\/i>, <b>12<\/b>, e0309921 (2021).","DOI":"10.1128\/mBio.03099-21"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Powers MJ, Trent MS. Intermembrane transport: glycerophospholipid homeostasis of the Gram-negative cell envelope. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>116<\/b>, 17147\u201317155 (2019).","DOI":"10.1073\/pnas.1902026116"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Powers MJ, Trent MS. Phospholipid retention in the absence of asymmetry strengthens the outer membrane permeability barrier to last-resort antibiotics. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>115<\/b>, E8518\u2013E8527 (2018).","DOI":"10.1073\/pnas.1806714115"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Park J, Kim M, Shin B, Kang M, Yang J, Lee TK, Park W. A novel decoy strategy for polymyxin resistance in <i>Acinetobacter baumannii<\/i>. <i>eLife<\/i>, <b>10<\/b>, e66988 (2021).","DOI":"10.7554\/eLife.66988"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Hood MI, Becker KW, Roux CM, Dunman PM, Skaar EP. Genetic determinants of intrinsic colistin tolerance in <i>Acinetobacter baumannii<\/i>. <i>Infect. Immun.<\/i>, <b>81<\/b>, 542\u2013551 (2013).","DOI":"10.1128\/IAI.00704-12"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Dafopoulou K, Xavier BB, Hotterbeekx A, Janssens L, Lammens C, De E, Goossens H, Tsakris A, Malhotra-Kumar S, Pournaras S. Colistin-resistant <i>Acinetobacter baumannii<\/i> clinical strains with deficient biofilm formation. <i>Antimicrob. Agents Chemother.<\/i>, <b>60<\/b>, 1892\u20131895 (2015).","DOI":"10.1128\/AAC.02518-15"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Lean SS, Suhaili Z, Ismail S, Rahman NI, Othman N, Abdullah FH, Jusoh Z, Yeo CC, Thong KL. Prevalence and genetic characterization of carbapenem- and polymyxin-resistant <i>Acinetobacter baumannii<\/i> isolated from a tertiary hospital in Terengganu, Malaysia. <i>ISRN Microbiol.<\/i>, <b>2014<\/b>, 953417 (2014).","DOI":"10.1155\/2014\/953417"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Bojkovic J, Richie DL, Six DA, Rath CM, Sawyer WS, Hu Q, Dean CR. Characterization of an <i>Acinetobacter baumannii<\/i> lptD deletion strain: permeability defects and response to inhibition of lipopolysaccharide and fatty acid biosynthesis. <i>J. Bacteriol.<\/i>, <b>198<\/b>, 731\u2013741 (2015).","DOI":"10.1128\/JB.00639-15"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Lin MF, Lin YY, Lan CY. Contribution of EmrAB efflux pumps to colistin resistance in <i>Acinetobacter baumannii<\/i>. <i>J. Microbiol.<\/i>, <b>55<\/b>, 130\u2013136 (2017).","DOI":"10.1007\/s12275-017-6408-5"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Ni W, Li Y, Guan J, Zhao J, Cui J, Wang R, Liu Y. Effects of efflux pump inhibitors on colistin resistance in multidrug-resistant gram-negative bacteria. <i>Antimicrob. Agents Chemother.<\/i>, <b>60<\/b>, 3215\u20133218 (2016).","DOI":"10.1128\/AAC.00248-16"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Park YK, Ko KS. Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing <i>Acinetobacter baumannii<\/i> by colistin. <i>J. Microbiol.<\/i>, <b>53<\/b>, 53\u201359 (2015).","DOI":"10.1007\/s12275-015-4498-5"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Lai SJ, Tu IF, Tseng TS, Tsai YH, Wu SH. The deficiency of poly-beta-1,6-<i>N<\/i>-acetyl-glucosamine deacetylase trigger <i>A. baumannii<\/i> to convert to biofilm-independent colistin-tolerant cells. <i>Sci. Rep.<\/i>, <b>13<\/b>, 2800 (2023).","DOI":"10.1038\/s41598-023-30065-5"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Sabnis A, Hagart KL, Klockner A, Becce M, Evans LE, Furniss RCD, Mavridou DA, Murphy R, Stevens MM, Davies JC, Larrouy-Maumus GJ, Clarke TB, Edwards AM. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. <i>eLife<\/i>, <b>10<\/b>, e65836 (2021).","DOI":"10.7554\/eLife.65836"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Olmeda-Lopez H, Corral-Lugo A, McConnell MJ. Effect of subinhibitory concentrations of antibiotics and disinfectants on ISAba-mediated inactivation of lipooligosaccharide biosynthesis genes in <i>Acinetobacter baumannii<\/i>. <i>Antibiotics<\/i> (Basel), <b>10<\/b>, 1259 (2021).","DOI":"10.3390\/antibiotics10101259"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in <i>Acinetobacter baumannii<\/i>. <i>Antimicrob. Agents Chemother.<\/i>, <b>55<\/b>, 3022\u20133024 (2011).","DOI":"10.1128\/AAC.01732-10"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Mustapha MM, Li B, Pacey MP, Mettus RT, McElheny CL, Marshall CW, Ernst RK, Cooper VS, Doi Y. Phylogenomics of colistin-susceptible and resistant XDR <i>Acinetobacter baumannii<\/i>. <i>J. Antimicrob. Chemother.<\/i>, <b>73<\/b>, 2952\u20132959 (2018).","DOI":"10.1093\/jac\/dky290"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Lima WG, Alves MC, Cruz WS, Paiva MC. Chromosomally encoded and plasmid-mediated polymyxins resistance in <i>Acinetobacter baumannii<\/i>: a huge public health threat. <i>Eur. J. Clin. Microbiol. Infect. Dis.<\/i>, <b>37<\/b>, 1009\u20131019 (2018).","DOI":"10.1007\/s10096-018-3223-9"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Karakonstantis S, Ioannou P, Kofteridis DD. In search for a synergistic combination against pandrug-resistant <i>A. baumannii<\/i>; methodological considerations. <i>Infection<\/i>, <b>50<\/b>, 569\u2013581 (2022).","DOI":"10.1007\/s15010-021-01748-w"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Abdul-Mutakabbir JC, Yim J, Nguyen L, Maassen PT, Stamper K, Shiekh Z, Kebriaei R, Shields RK, Castanheira M, Kaye KS, Rybak MJ. <i>In vitro<\/i> synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant <i>Acinetobacter baumannii<\/i>. <i>Antibiotics<\/i> (Basel), <b>10<\/b>, 880 (2021).","DOI":"10.3390\/antibiotics10070880"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Sertcelik A, Baran I, Akinci E, Mumcuoglu I, Bodur H. Synergistic activities of colistin combinations with meropenem, sulbactam, minocycline, disodium fosfomycin, or vancomycin against different clones of carbapenem-resistant <i>Acinetobacter baumannii<\/i> strains. <i>Microb. Drug Resist.<\/i>, <b>26<\/b>, 429\u2013433 (2020).","DOI":"10.1089\/mdr.2019.0088"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Bardbari AM, Arabestani MR, Karami M, Keramat F, Aghazadeh H, Alikhani MY, Bagheri KP. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of <i>Acinetobacter baumannii<\/i>. <i>Eur. J. Clin. Microbiol. Infect. Dis.<\/i>, <b>37<\/b>, 443\u2013454 (2018).","DOI":"10.1007\/s10096-018-3189-7"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Soudeiha MAH, Dahdouh EA, Azar E, Sarkis DK, Daoud Z. <i>In vitro<\/i> evaluation of the colistin-carbapenem combination in clinical isolates of <i>A. baumannii<\/i> using the checkerboard, etest, and time-kill curve techniques. <i>Front. Cell. Infect. Microbiol.<\/i>, <b>7<\/b>, 209 (2017).","DOI":"10.3389\/fcimb.2017.00209"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. <i>Antimicrob. Agents Chemother.<\/i>, <b>52<\/b>, 333\u2013336 (2008).","DOI":"10.1128\/AAC.00689-07"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Qureshi ZA, Hittle LE, O\u2019Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. <i>Clin. Infect. Dis.<\/i>, <b>60<\/b>, 1295\u20131303 (2015).","DOI":"10.1093\/cid\/civ048"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Dickstein Y, Lellouche J, Ben Dalak Amar M, et al. Treatment outcomes of colistin- and carbapenem-resistant <i>Acinetobacter baumannii<\/i> infections: an exploratory subgroup analysis of a randomized clinical trial. <i>Clin. Infect. Dis.<\/i>, <b>69<\/b>, 769\u2013776 (2019).","DOI":"10.1093\/cid\/ciy988"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone <i>versus<\/i> colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infect. Dis.<\/i>, <b>18<\/b>, 391\u2013400 (2018).","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Garc\u00eda-Quintanilla M, Carretero-Ledesma M, Moreno-Mart\u00ednez P, Martin-Pe\u00f1a R, Pach\u00f3n J, McConnell MJ. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii. <i>Int. J. Antimicrob. Agents<\/i>, <b>46<\/b>, 696\u2013702 (2015).","DOI":"10.1016\/j.ijantimicag.2015.07.017"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. <i>Antimicrob. Agents Chemother.<\/i>, <b>58<\/b>, 518\u2013526 (2014).","DOI":"10.1128\/AAC.01597-13"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) L\u00f3pez-Rojas R, McConnell MJ, Jim\u00e9nez-Mej\u00edas ME, Dom\u00ednguez-Herrera J, Fern\u00e1ndez-Cuenca F, Pach\u00f3n J. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. <i>Antimicrob. Agents Chemother.<\/i>, <b>57<\/b>, 4587\u20134589 (2013).","DOI":"10.1128\/AAC.00543-13"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Moffatt JH, Harper M, Mansell A, Crane B, Fitzsimons TC, Nation RL, Li J, Adler B, Boyce JD. Lipopolysaccharide-deficient <i>Acinetobacter baumannii<\/i> shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. <i>Infect. Immun.<\/i>, <b>81<\/b>, 684\u2013689 (2013).","DOI":"10.1128\/IAI.01362-12"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Karakonstantis S. A systematic review of implications, mechanisms, and stability of <i>in vivo<\/i> emergent resistance to colistin and tigecycline in <i>Acinetobacter baumannii<\/i>. <i>J. Chemother.<\/i>, <b>33<\/b>, 1\u201311 (2021).","DOI":"10.1080\/1120009X.2020.1794393"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Gerson S, Betts JW, Lucassen K, Nodari CS, Wille J, Josten M, Gottig S, Nowak J, Stefanik D, Roca I, Vila J, Cisneros JM, La Ragione RM, Seifert H, Higgins PG. Investigation of novel <i>pmrB<\/i> and <i>eptA<\/i> mutations in isogenic <i>Acinetobacter baumannii<\/i> isolates associated with colistin resistance and increased virulence <i>in vivo<\/i>. <i>Antimicrob. Agents Chemother.<\/i>, <b>63<\/b>, e01586\u201318 (2019).","DOI":"10.1128\/AAC.01586-18"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. Emergence of colistin-resistance in extremely drug-resistant <i>Acinetobacter baumannii<\/i> containing a novel pmrCAB operon during colistin therapy of wound infections. <i>J. Infect. Dis.<\/i>, <b>208<\/b>, 1142\u20131151 (2013).","DOI":"10.1093\/infdis\/jit293"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) L\u00f3pez-Rojas R, Dom\u00ednguez-Herrera J, McConnell MJ, Docobo-Per\u00e9z F, Smani Y, Fern\u00e1ndez-Reyes M, Rivas L, Pach\u00f3n J. Impaired virulence and <i>in vivo<\/i> fitness of colistin-resistant <i>Acinetobacter baumannii<\/i>. <i>J. Infect. Dis.<\/i>, <b>203<\/b>, 545\u2013548 (2011).","DOI":"10.1093\/infdis\/jiq086"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Kim SH, Yun S, Park W. Constitutive phenotypic modification of lipid A in clinical <i>Acinetobacter baumannii<\/i> isolates. <i>Microbiol. Spectr.<\/i>, <b>10<\/b>, e0129522 (2022).","DOI":"10.1128\/spectrum.01295-22"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Novovi\u0107 K, Jov\u010di\u0107 B. Colistin resistance in <i>Acinetobacter baumannii<\/i>: molecular mechanisms and epidemiology. <i>Antibiotics<\/i> (Basel), <b>12<\/b>, 516 (2023).","DOI":"10.3390\/antibiotics12030516"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Zhang Q, Wang R, Wang M, Liu C, Koohi-Moghadam M, Wang H, Ho PL, Li H, Sun H. Re-sensitization of <i>mcr<\/i> carrying multidrug resistant bacteria to colistin by silver. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>119<\/b>, e2119417119 (2022).","DOI":"10.1073\/pnas.2119417119"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Chamoun S, Welander J, Martis-Thiele MM, Ntzouni M, Claesson C, Vikstrom E, Turkina MV. Colistin dependence in extensively drug-resistant <i>Acinetobacter baumannii<\/i> strain is associated with <i>ISAjo2<\/i> and I<i>SAba13<\/i> insertions and multiple cellular responses. <i>Int. J. Mol. Sci.<\/i>, <b>22<\/b>, 576 (2021).","DOI":"10.3390\/ijms22020576"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Kon H, Hameir A, Temkin E, Keren-Paz A, Schwartz D, Schechner V, Carmeli Y. Colistin dependency among colistin-heteroresistant <i>Acinetobacter baumannii<\/i> isolates. <i>Microorganisms<\/i>, <b>10<\/b>, 58 (2021).","DOI":"10.3390\/microorganisms10010058"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Lee JY, Lee H, Park M, Cha CJ, Shin D, Ko KS. Lytic transglycosylase contributes to the survival of lipooligosaccharide-deficient, colistin-dependent Acinetobacter baumannii. <i>Clin. Microbiol. Infect.<\/i>, <b>25<\/b>, 1156.e1\u20131156.e7 (2019).","DOI":"10.1016\/j.cmi.2019.02.004"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Hong YK, Lee JY, Wi YM, Ko KS. High rate of colistin dependence in <i>Acinetobacter baumannii<\/i>. <i>J. Antimicrob. Chemother.<\/i>, <b>71<\/b>, 2346\u20132348 (2016).","DOI":"10.1093\/jac\/dkw121"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Zhu Y, Lu J, Han ML, et al. Polymyxins bind to the cell surface of unculturable <i>Acinetobacter baumannii<\/i> and cause unique dependent resistance. <i>Adv. Sci. (Weinh.)<\/i>, <b>7<\/b>, 2000704 (2020).","DOI":"10.1002\/advs.202070082"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Jo J, Ko KS. Tigecycline heteroresistance and resistance mechanism in clinical isolates of <i>Acinetobacter baumannii<\/i>. <i>Microbiol. Spectr.<\/i>, <b>9<\/b>, e0101021 (2021).","DOI":"10.1128\/Spectrum.01010-21"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. <i>Clin. Microbiol. Rev.<\/i>, <b>28<\/b>, 191\u2013207 (2015).","DOI":"10.1128\/CMR.00058-14"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Rodriguez CH, Traglia G, Bastias N, Pandolfo C, Bruni G, Nastro M, Barrios R, Bavastro EM, Rey MC, Marques IA, Heger F, Vay C, Fernandez JS, Ramirez MS, Famiglietti A. Discrepancies in susceptibility testing to colistin in <i>Acinetobacter baumannii<\/i>: the influence of slow growth and heteroresistance. <i>Int. J. Antimicrob. Agents<\/i>, <b>54<\/b>, 587\u2013591 (2019).","DOI":"10.1016\/j.ijantimicag.2019.08.010"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Barth VC Jr, Rodrigues BA, Bonatto GD, Gallo SW, Pagnussatti VE, Ferreira CA, de Oliveira SD. Heterogeneous persister cells formation in <i>Acinetobacter baumannii<\/i>. <i>PLOS ONE<\/i>, <b>8<\/b>, e84361 <b>(<\/b>2013).","DOI":"10.1371\/journal.pone.0084361"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. Heteroresistance to colistin in multidrug-resistant <i>Acinetobacter baumannii<\/i>. <i>Antimicrob. Agents Chemother.<\/i>, <b>50<\/b>, 2946\u20132950 (2006).","DOI":"10.1128\/AAC.00103-06"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Snitkin ES, Zelazny AM, Gupta J, Program NCS, Palmore TN, Murray PR, Segre JA. Genomic insights into the fate of colistin resistance and <i>Acinetobacter baumannii<\/i> during patient treatment. <i>Genome Res<\/i>., <b>23<\/b>, 1155\u20131162 (2013).","DOI":"10.1101\/gr.154328.112"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. <i>Int. J. Antimicrob. Agents<\/i>, <b>56<\/b>, 106065 (2020).","DOI":"10.1016\/j.ijantimicag.2020.106065"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Dewachter L, Fauvart M, Michiels J. Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance. <i>Mol. Cell<\/i>, <b>76<\/b>, 255\u2013267 (2019).","DOI":"10.1016\/j.molcel.2019.09.028"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/3\/48_b23-00642\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:33:11Z","timestamp":1740799991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/3\/48_b23-00642\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00642","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"article-number":"b23-00642"}}